Abstract
In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 8-12 |
| Number of pages | 5 |
| Journal | Seminars in Oncology |
| Volume | 15 |
| Issue number | 6 SUPPL. 7 |
| State | Published - 1988 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
Preoperative and adjuvant chemotherapy in non-small cell lung cancer. / Gralla, Richard J.
In: Seminars in Oncology, Vol. 15, No. 6 SUPPL. 7, 1988, p. 8-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Preoperative and adjuvant chemotherapy in non-small cell lung cancer
AU - Gralla, Richard J.
PY - 1988
Y1 - 1988
N2 - In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.
AB - In non-small cell lung cancer (NSCLC), if the tumor is completely resected in stage I, II, and IIIa disease, the outlook is favorable. In stage IIIa disease, preoperative chemotherapy is efficacious and also confers the potential for improved resectability rates and survival. In a study of 58 patients with locally advanced (stage IIIa) NSCLC, preoperative combination chemotherapy with mitomycin C, cisplatin, and vinca alkaloids yielded 7 complete responses and 37 partial responses. Of the 44 patients with major responses, 42 were surgically explored and 33 were completely resected. Nine patients had pathologically negative biopsy specimens. The median survival for all patients thus far is 19.5 months. These results indicate that surgery can be performed safely in patients treated preoperatively with currently available chemotherapeutic agents. Moreover, complete resections are feasible and can be accomplished in a majority of patients.
UR - http://www.scopus.com/inward/record.url?scp=0024210301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024210301&partnerID=8YFLogxK
M3 - Article
C2 - 2851182
AN - SCOPUS:0024210301
VL - 15
SP - 8
EP - 12
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 6 SUPPL. 7
ER -